Program
Bupropion
Also written as “bupropion hydrochloride”, “Extended-release Bupropion Hydrochloride” and “Extended-release bupropion hydrochloride”.
Its studies are mostly in Smoking Cessation · Depressive Disorder, Major · Depressive Disorder · Seasonal Affective Disorder · Obesity, led by 6 companies.
Drug pageBupropion: every studyMany companies study it; this page follows only the 19 they lead. All 217 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 80 open or running | phase 3since Sep 24, 2002 | Sep 24, 2002 | none ahead |
| Teva Pharmaceutical Industriesits history only | 60 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Rose Research Centerits history only | 20 open or running | phase 3since May 11, 2020 | May 11, 2020 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 1since Oct 2, 2015 | Oct 2, 2015 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Apr 16, 2009 | Apr 16, 2009 | none ahead |
| Takedaits history only | 10 open or running | phase 4since Nov 24, 2015 | Nov 24, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2002First study: phase 3 study in Seasonal Affective DisorderNew to GlaxoSmithKlineGlaxoSmithKline · NCT00046241 · 300 enrolled · United States, Canada
- Oct 30, 2002Phase 3 study in Attention Deficit Disorder with HyperactivityGlaxoSmithKline · NCT00048360 · 162 enrolled · United States
- Jan 7, 20032 phase 3 studies in Depressive Disorder, MajorGlaxoSmithKline · NCT00051272, NCT00051259
- Sep 25, 2003Phase 1 study in Depressive DisorderGlaxoSmithKline · NCT00069459 · 250 enrolled · United States
- Oct 5, 2004Phase 3 study in Depressive Disorder, MajorGlaxoSmithKline · NCT00093288 · 364 enrolled · Australia, Belgium, Finland and more
- Aug 24, 2005Phase 2 study in Depressive DisorderGlaxoSmithKline · NCT00135512 · 234 enrolled · Japan
- Mar 17, 2009Teva Pharmaceutical Industries’ first studies: 5 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00865462, NCT00865410, NCT00865371 and 2 more
- Apr 16, 2009Novartis’s first study: phase 1 study in HealthyNew to NovartisNovartis · NCT00883155 · 36 enrolled
- Jan 8, 2010Phase 1 study in Depressive DisorderTeva Pharmaceutical Industries · NCT01046214 · 8 enrolled · United States
- Jul 14, 2014Phase 3 study in Depressive Disorder, MajorGlaxoSmithKline · NCT02191397 · 534 enrolled · China
- Oct 2, 2015Johnson & Johnson’s first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT02568176 · 71 enrolled · Belgium
- Nov 24, 2015Takeda’s first study: phase 4 study in Weight Regain Post Bariatric SurgeryNew to TakedaTakeda · NCT02616315 · United States
- May 11, 2020Rose Research Center’s first study: phase 3 study in Smoking CessationNew to Rose Research CenterRose Research Center · NCT04388319 · 26 enrolled · United States
- Oct 27, 2021Phase 3 study in Smoking CessationRose Research Center · NCT05205811 · 180 enrolled · United States
TargetBeta
“Dopamine transporter inhibitor; Dopamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| dexmethylphenidaterule | cingulate-therapeutics | phase 4 | 14 |
| Amphetaminerule | Tris Pharma | phase 4 | 8 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05205811Smoking Cessation · United States | 3 | Completed | Rose Research Center | Jun 19, 2025 | 180 |
| NCT04388319Smoking Cessation · United States | 3 | Completed | Rose Research Center | Jun 4, 2021 | 26 |
| NCT02616315Weight Regain Post Bariatric Surgery · United States | 4 | Withdrawn | Takeda | Oct 2017 | 0 |
| NCT02568176Healthy · Belgium | 1 | Completed | Johnson & Johnson | Feb 2016 | 71 |
| NCT02191397Depressive Disorder, Major · China | 3 | Completed | GlaxoSmithKline | Oct 10, 2016 | 534 |
| NCT01046214Depressive Disorder · United States | 1 | Terminated | Teva Pharmaceutical Industries | 8 | |
| NCT00883155Healthy | 1 | Completed | Novartis | Oct 1998 | 36 |
| NCT00865462Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2004 | 30 |
| NCT00865410Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2004 | 26 |
| NCT00865371Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2004 | 26 |
| NCT00865111Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Apr 2006 | 26 |
| NCT00863941Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2004 | 28 |
| NCT00135512Depressive Disorder · Japan | 2 | Completed | GlaxoSmithKline | May 28, 2007 | 234 |
| NCT00093288Depressive Disorder, Major · Australia, Belgium, Finland and more | 3 | Completed | GlaxoSmithKline | Oct 2005 | 364 |
| NCT00069459Depressive Disorder · United States | 1 | Completed | GlaxoSmithKline | Jun 3, 2004 | 250 |
| NCT00051272Depressive Disorder, Major · United States | 3 | Completed | GlaxoSmithKline | Jun 2004 | 425 |
| NCT00051259Depressive Disorder, Major · United States | 3 | Completed | GlaxoSmithKline | Jun 2004 | 420 |
| NCT00048360Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | GlaxoSmithKline | Jun 2003 | 162 |
| NCT00046241Seasonal Affective Disorder · United States, Canada | 3 | Completed | GlaxoSmithKline | Jun 2003 | 300 |
How it is read
Names in the registry
- “Bupropion”, 7 entries
- “bupropion hydrochloride”, 3 entries
- “Extended-release Bupropion Hydrochloride”, 2 entries
- “Extended-release bupropion hydrochloride”, 2 entries
- “Bupropion HCl”, 2 entries
Conditions, from the studies’ own filings
- Smoking Cessation, 5 studies
- Depressive Disorder, Major, 4 studies
- Depressive Disorder, 2 studies
- Seasonal Affective Disorder, 2 studies
- Obesity, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.